Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Update: Desmopressin nasal spray is no longer indicated to treat PNE

  • Comment

Indication for the treatment of PNE has been removed from all desmopressin nasal spray products at the request of the Medicines and Healthcare products Regulatory Agency

Compared with oral formulations of desmopressin, nasal forms have been associated with most of the serious adverse drug reactions reported in patients with PNE. Rare and serious adverse drug reactions reported have included hyponatraemia, water intoxication and convulsions.

Patients may complete their current course of treatment with desmopressin nasal spray but, at the next routine review, those requiring continued treatment should be prescribed an oral form of desmopressin.

All patients who start treatment with oral desmopressin should start at the lowest recommended dose, regardless of the dose of spray they have been taking. This should only be increased to achieve control of symptoms.

Go to, click on ‘Safety information’ then ‘Safety warnings, alerts and recalls’. Scroll to 18 April, ‘Desmopressin nasal spray: removal of the primary nocturnal enuresis (bedwetting) indication’.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs